Dassanayake TL, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, et al. Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series study in Australia. CNS Drugs 2012;26(3):269-76. https://www.ncbi.nlm.nih.gov/pubmed/22329565
Dassanayake TL, Michie PT, Jones AL, Mallard T, Whyte IM, Carter GL. Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs. Traffic Inj Prev 2012;13(5):450-7. https://www.ncbi.nlm.nih.gov/pubmed/22931174
Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008;30(4):490-6. https://www.ncbi.nlm.nih.gov/pubmed/18641540
Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362(2):116-21. https://www.ncbi.nlm.nih.gov/pubmed/10961373
Habibollahi P, Garjani A, Shams Vahdati S, Sadat-Ebrahimi SR, Parnianfard N. Severe complications of tramadol overdose in Iran. Epidemiol Health 2019;41:e2019026. https://www.ncbi.nlm.nih.gov/pubmed/31208192
Hara K, Minami K, Sata T. The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg 2005;100(5):1400-5. https://www.ncbi.nlm.nih.gov/pubmed/15845694
Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al.
Pharmacokinetic properties and human use characteristics of an FDA-approved
intranasal naloxone product for the treatment of opioid overdose. J Clin
Pharmacol 2016;56(10):1243–53. https://www.ncbi.nlm.nih.gov/pubmed/27145977
Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol (Phila) 2015;53(6):545-50. https://www.ncbi.nlm.nih.gov/pubmed/25901965
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9(1):63-88. https://www.ncbi.nlm.nih.gov/pubmed/29318006
Spiller HA, Gorman SE, Villalobos D, Benson BE, Ruskosky DR, Stancavage MM, et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol 1997;35(4):361-4. https://www.ncbi.nlm.nih.gov/pubmed/9204095
Xu J, Zhang XC, Lv XQ, Xu YY, Wang GX, Jiang B, et al. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Pharmazie 2014;69(2):138-41. https://www.ncbi.nlm.nih.gov/pubmed/24640604
